Conventional Therapies Deplete Brain-Infiltrating Adaptive Immune Cells in a Mouse Model of Group 3 Medulloblastoma Implicating Myeloid Cells as Favorable Immunotherapy Targets
Medulloblastoma is the most common childhood brain cancer. Mainstay treatments of radiation and chemotherapy have not changed in decades and new treatment approaches are crucial for the improvement of clinical outcomes. To date, immunotherapies for medulloblastoma have been unsuccessful, and studies...
Main Authors: | Zahra Abbas, Courtney George, Mathew Ancliffe, Meegan Howlett, Anya C. Jones, Mani Kuchibhotla, Robert J. Wechsler-Reya, Nicholas G. Gottardo, Raelene Endersby |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.837013/full |
Similar Items
-
Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma
by: Jessica Buck, et al.
Published: (2021-04-01) -
Assessment of Cannabidiol and Δ9-Tetrahydrocannabiol in Mouse Models of Medulloblastoma and Ependymoma
by: Clara Andradas, et al.
Published: (2021-01-01) -
Editorial: Bench to bedside: translating pre-clinical research into clinical trials for childhood brain tumors
by: Raelene Endersby, et al.
Published: (2023-08-01) -
Radiotherapy in Medulloblastoma—Evolution of Treatment, Current Concepts and Future Perspectives
by: Clemens Seidel, et al.
Published: (2021-11-01) -
Craniospinal Irradiation of Pediatric Medulloblastoma, Dosimetric Comparison between Helical Tomotherapy, and Conventional Radiation Therapy
by: Mohamed Hegazy, et al.
Published: (2022-10-01)